Labcorp launches new test for people with skin cancer

BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2022-- Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company.

Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection

BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.

Labcorp to speak at the UBS 2022 Global Healthcare conference

BURLINGTON, N.C. --(BUSINESS WIRE)--May 17, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 at 2:45 p.m. ET.

Labcorp launches first-of-its-kind at-home collection device for diabetes risk testing

BURLINGTON, N.C. --(BUSINESS WIRE)--May 16, 2022-- There is a new and convenient way for millions of individuals to assess whether they are at risk for developing diabetes.

Jeffrey Albrecht

Dr Albrecht earned his PhD in microbiology and molecular genetics from the University of California at Los Angeles. He also holds New York state certification of qualification in genetic testing and is licensed in California as a clinical genetics molecular biologist scientist.